0
0The global pharmaceutical and healthcare landscape is changing faster than many expected.
China is now the world’s second largest healthcare market, valued at over one trillion US dollars. But the real shift isn’t about demand. It’s about capability.
In the first half of 2025 alone, Chinese biotech transactions accounted for 44 percent of global deal volume. This signals something deeper than market expansion.
We are seeing a transition from manufacturing to innovation.
From producing for global markets to developing original therapies that compete internationally.
This episode looks at China’s healthcare sector from an overseas observer’s perspective. Not as a story of national growth, but as a case study in how innovation ecosystems evolve, how capital flows follow capability, and where future healthcare breakthroughs may come from.
Understanding these shifts matters for investors, researchers, and anyone watching the next generation of global technology.
#CNQQ #Rayliant #ChinaNextGenTechWave #Healthcare #Biotech #GlobalHealthcare #TechInnovation #Investing
